What Celltrion Pharm does

Celltrion Pharm, Inc. (셀트리온제약, KOSDAQ: KS200026) is a South Korea-based pharmaceutical manufacturer founded in 2000 and operating as a publicly listed subsidiary of Celltrion Group since 2009. The company produces and sells a portfolio of 12 biosimilar products and a broad line of chemical pharmaceuticals across autoimmune disease, oncology, allergy, liver disease, and cardiovascular therapeutic areas. Its flagship biosimilars include Remsima (world's first infliximab biosimilar), Remsima SC (world's first subcutaneous infliximab biosimilar), Truxima (rituximab), Herzuma (trastuzumab), and Vegzelma (bevacizumab); the chemical portfolio is anchored by Godex, the #1 outpatient liver-treatment brand in Korea. The company also operates a CMO business for oral solid dosage and PFS biopharmaceutical manufacturing under FDA, EMA, PMDA, and ANVISA GMP certifications.

Celltrion Pharm's technology platform spans biosimilar cell-line and process development, antibody-drug conjugate (ADC) research, subcutaneous and autoinjector formulation know-how, and nano/microsphere drug delivery systems. Manufacturing is concentrated at the GMP-certified Cheongju plant (OSD and PFS) and the Jincheon plant (chemical products), with research based at the Songdo Global Biotech Research Center. The company sells exclusively through Korean domestic channels — nine regional branch offices, medical representative coverage of hospitals and clinics, and a dedicated e-order system for registered pharmaceutical distributors — with end customers being healthcare providers and pharmacies whose purchases are reimbursed under the Korean National Health Insurance system.

In FY2025, Celltrion Pharm reported record revenue of 536.4 billion KRW, the first time the company exceeded 500 billion KRW in annual sales, supported by 1,006 employees. The company's commercial model is a sales-led enterprise field-sales motion with academic symposia, with revenue generated through prescription pharmaceutical sales, CMO services, and a regulated NHI pricing framework. Celltrion Group retains majority ownership and strategic oversight.

Name

Celltrion Pharm

Legal name

주식회사 셀트리온제약 (Celltrion Pharm, Inc.)

Website

https://celltrionph.com:444

Company type

Public

Founded year

2000

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Celltrion Pharm is a South Korea-based, KOSDAQ-listed pharmaceutical manufacturer selling a portfolio of 12 biosimilars and chemical drugs to Korean hospitals, clinics, and pharmacies through medical representatives and distributors, supported by globally GMP-certified manufacturing facilities.

Ownership category

akta.pro rank

Product category

Biosimilar Pharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)

akta.pro secondary industries

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), Specialty Pharma & Biologics Distribution (GDP-compliant) (HLAGAMAD), Small-Molecule Generics (Branded/Unbranded) (HLAIABAA)

Keywords

• Biosimilar pharmaceuticals
• Chemical pharmaceuticals
• Contract manufacturing
• Drug delivery systems
• Antibody drug conjugates

Headquarters

HQ city

Cheongju (청주)

HQ country

South Korea

HQ region

Asia

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Technology or R&D, Marketing or Sales, Personnel

Revenue model

1. Biosimilar Drug Sales: Sale of biosimilar pharmaceutical products including Remsima, Truxima, Herzuma, Vegzelma, Yuplima, and other autoimmune/cancer treatments in Korean domestic market
2. Chemical Drug Sales: Sale of chemical pharmaceutical products including cardiovascular, endocrine, digestive, antibiotic treatments. Major product Godex leads liver treatment market. Achieved first 500 billion KRW annual sales milestone.
3. CMO Services: Contract manufacturing services for OSD (oral solid dosage) and PFS (pre-filled syringe) formulations under global GMP standards for domestic and international partners

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Celltrion Pharm manufactures and sells biosimilar and chemical pharmaceutical products in the Korean domestic market, with a portfolio of 12 biosimilars (including Remsima, Truxima, Herzuma, Vegzelma) and chemical drugs (including Godex for liver disease and combination antihypertensives). The company also provides contract manufacturing (CMO) services for oral solid dosage (OSD) and pre-filled syringe (PFS) formulations to domestic and international pharmaceutical partners under global GMP standards.

Product overview

Celltrion Pharm is a Korean pharmaceutical company offering both chemical and biosimilar products, with a portfolio of 12 biosimilar products and diverse chemical medications across therapeutic areas including cardiovascular, endocrine, digestive, and liver diseases. The chemical portfolio includes market-leading products like Godex for liver disease and combination antihypertensives like Treble Tab and Idaldipine. The biosimilar portfolio features world-first antibody biosimilars including Remsima (infliximab), Truxima (rituximab), Herzuma (trastuzumab), and newer products like Vegzelma, Yuplima, Stelima, Stoboclo, Osenbelt, Omilclo, Aputozimab, and Ayden Jelt. The company also provides CMO services for both chemical (tablets, capsules) and biopharmaceutical (PFS, autoinjector) manufacturing, supported by globally certified production facilities. An E-Order system serves distributor logistics.

Differentiator

Problem solved

Functional benefit

Products and services

• Remsima (램시마주) - Infliximab Biosimilar
• Remsima SC - Subcutaneous Infliximab Biosimilar
• Truxima (트룩시마주) - Rituximab Biosimilar
• Herzuma (허주마주) - Trastuzumab Biosimilar
• Vegzelma (베그젤마) - Bevacizumab Biosimilar
• Yuplima (유플라이마) - Secukinumab Biosimilar
• Stoboclo (스토보클로) - Denosumab Biosimilar
• Osenbelt (오센벨트) - Denosumab Biosimilar
• Omilclo (옴리클로) - Omalizumab Biosimilar
• Aputozimab (앱토즈마) - Tocilizumab Biosimilar
• Stekima (스테키마) - Biosimilar
• Idenzel (아이덴젤트) - Ophthalmic Biosimilar
• Eptozma (엡토즈마) - Tocilizumab Biosimilar
• Godex Capsule (고덱스캡슐) - Liver Disease Treatment

Quantifiable outcome

• Remsima cumulative sales of 3,008 billion KRW as of December 2025
• +2 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators6 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Samsung Bioepis: Samsung Group-backed biosimilar developer commercializing multiple mAb biosimilars (Renflexis, Imraldi, Ontruzant, etc.) globally and in Korea. Direct head-to-head competitor across autoimmune and oncology biosimilar franchises in Korean hospitals.
• Celltrion Inc. Sister company within Celltrion Group that develops and globally commercializes the same biosimilar molecules (Remsima, Truxima, Herzuma) that Celltrion Pharm distributes in Korea. Closest comparable in therapeutic scope, but Celltrion Inc operates globally while Celltrion Pharm is Korea-only.
• GC Pharma (formerly Green Cross Corporation): One of Korea's largest pharmaceutical companies with a broad biosimilar, blood plasma, and vaccine portfolio. Comparable in scale, business mix (biologics + small molecule), and Korean hospital-channel GTM.
• Alteogen: Korean biosimilar and biobetter developer with a pipeline targeting key mAb franchises. Competes directly for Korean biosimilar market share and has proprietary SC delivery technology (Hybrozyme) that parallels Celltrion Pharm's Remsima SC approach.
• Hanmi Pharmaceutical: Major Korean pharma with biosimilars, innovative small molecules (HM-Brex, Efpegerglucagon), and proprietary drug delivery platforms. Comparable in mixed biologics/small-molecule strategy and Korean commercial focus.

Broad incumbents

• Samsung Biologics: World's largest biologics contract manufacturer by capacity. Comparable in biopharmaceutical manufacturing expertise, global GMP certifications, and PFS/aseptic fill-finish capability — but operates purely as a CDMO without proprietary commercial products.
• Amgen: Global biopharmaceutical leader that both develops reference biologics and markets biosimilars (Amgevita, Kanjinti). Comparable as a competitor and counterparty in the Korean biosimilar market, with broader global reach.

Regional players

• Daewoong Pharmaceutical: Mid-sized Korean pharma with strong small-molecule portfolio, biosimilars (DWP710001), and international expansion ambitions. Comparable as a domestic Korean pharma competitor in shared hospital channels.
• Yuhan Corporation: Korea's largest pharmaceutical company by sales, with a diversified branded generics and innovative drug portfolio. Comparable as a Korean-market pharma with similar NHI pricing exposure and hospital-channel commercial model.
• Dong-A Pharmaceutical: Long-established Korean pharma with branded small-molecule portfolio and growing biosimilar activities. Comparable as a domestic Korean pharma operating under the same NHI pricing regime.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/celltrionpharm

Compliance9 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Celltrion Pharm